Identifying immune-related prognostic biomarkers in osteosarcoma: Development and validation of the tumor immune microenvironment risk model based on analysis of TCGA
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers developed a new seven-gene prognostic model for osteosarcoma, called TIMErisk. This model predicts patient survival and response to immunotherapy by analyzing the tumor immune microenvironment (TIME).
Area Of Science
- Oncology
- Immunology
- Genomics
Background
- Osteosarcoma is an aggressive cancer with few treatment options.
- The tumor immune microenvironment (TIME) plays a critical role in cancer progression.
- Identifying prognostic biomarkers is crucial for effective osteosarcoma management.
Purpose Of The Study
- To identify immune-related prognostic biomarkers for osteosarcoma.
- To develop a predictive model for osteosarcoma patient prognosis and immunotherapy response.
Main Methods
- Integrated analysis of transcriptomic data and immune cell infiltration from 84 osteosarcoma samples (TCGA database).
- Development and validation of the TIMErisk prognostic model using time-dependent ROC curve analysis.
- Functional annotation and pathway enrichment analyses to explore underlying mechanisms.
Main Results
- A seven-gene TIMErisk model (C2, APBB1IP, BST2, TRPV2, CCL5, GBP1, F13A1) was identified, independently predicting overall survival in osteosarcoma patients.
- The TIMErisk model correlated with immune cell infiltration, immunosuppressive gene expression, and drug sensitivity.
- Differential expression of immune checkpoint genes was observed between high- and low-TIMErisk groups.
- Pathway analyses linked the TIMErisk model to antigen processing, cytokine-cytokine receptor interaction, and T cell receptor signaling.
Conclusions
- A novel TIME-based prognostic model (TIMErisk) for osteosarcoma was developed.
- The TIMErisk model can predict patient prognosis and response to immunotherapy.
- Immune-related biomarkers and the TIME microenvironment are significant in osteosarcoma progression and clinical management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
